Quantum Private Wealth LLC lessened its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 26.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,775 shares of the medical research company's stock after selling 16,499 shares during the period. Exact Sciences makes up about 0.8% of Quantum Private Wealth LLC's portfolio, making the stock its 21st biggest position. Quantum Private Wealth LLC's holdings in Exact Sciences were worth $2,572,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also bought and sold shares of the company. Thompson Investment Management Inc. grew its holdings in shares of Exact Sciences by 17.8% during the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock valued at $13,585,000 after buying an additional 36,505 shares during the last quarter. WCM Investment Management LLC grew its stake in Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company's stock valued at $12,388,000 after purchasing an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. grew its stake in Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company's stock valued at $1,994,000 after purchasing an additional 11,800 shares during the last quarter. Zacks Investment Management acquired a new position in shares of Exact Sciences in the third quarter valued at about $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Exact Sciences by 59.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company's stock worth $22,868,000 after purchasing an additional 125,192 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.
Exact Sciences Price Performance
Shares of EXAS traded up $0.85 during mid-day trading on Wednesday, hitting $50.48. 3,349,257 shares of the company were exchanged, compared to its average volume of 2,213,045. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The stock has a market cap of $9.34 billion, a price-to-earnings ratio of -43.14 and a beta of 1.24. The company has a 50 day moving average of $55.41 and a 200-day moving average of $60.10.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Analysts expect that Exact Sciences Co. will post -1.1 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on EXAS. Piper Sandler cut their price target on shares of Exact Sciences from $85.00 to $75.00 and set an "overweight" rating on the stock in a report on Monday, November 11th. Benchmark reiterated a "buy" rating and issued a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. Bank of America lowered their price target on shares of Exact Sciences from $75.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, December 13th. BTIG Research lifted their price objective on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Sanford C. Bernstein boosted their price objective on Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $72.76.
Get Our Latest Stock Analysis on EXAS
Exact Sciences Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
